AU2011239683A1 - Compositions and methods for treating visual disorders - Google Patents
Compositions and methods for treating visual disorders Download PDFInfo
- Publication number
- AU2011239683A1 AU2011239683A1 AU2011239683A AU2011239683A AU2011239683A1 AU 2011239683 A1 AU2011239683 A1 AU 2011239683A1 AU 2011239683 A AU2011239683 A AU 2011239683A AU 2011239683 A AU2011239683 A AU 2011239683A AU 2011239683 A1 AU2011239683 A1 AU 2011239683A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- substituted
- retinal
- oil
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32463210P | 2010-04-15 | 2010-04-15 | |
| US61/324,632 | 2010-04-15 | ||
| PCT/US2011/032325 WO2011130411A1 (en) | 2010-04-15 | 2011-04-13 | Compositions and methods for treating visual disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2011239683A1 true AU2011239683A1 (en) | 2012-11-08 |
Family
ID=44009992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011239683A Abandoned AU2011239683A1 (en) | 2010-04-15 | 2011-04-13 | Compositions and methods for treating visual disorders |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110257186A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2558100A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2013523892A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20130092976A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011239683A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2796345A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2012148214A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011130411A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201600127037A1 (it) * | 2016-12-15 | 2018-06-15 | Oftalab S R L | Soluzione oftalmica di verde di lissamina e suo uso in oftalmologia |
| CN109908327A (zh) * | 2019-03-12 | 2019-06-21 | 广州陈锦济生物科技有限公司 | 一种用于治疗近视的眼药水及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| PL378366A1 (pl) * | 2003-01-13 | 2006-04-03 | Cortex Pharmaceuticals, Inc. | Sposób leczenia osłabienia funkcji poznawczych spowodowanego deprywacją snu i stresem |
| EP2010174A4 (en) * | 2006-04-20 | 2012-05-09 | Univ California | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA-RECEPTOR MODULATOR EFFECT ON NEUROTROPHINEXPRESSION |
| US20080139472A1 (en) * | 2006-10-06 | 2008-06-12 | The Regents Of The University Of California | Upregulating bdnf levels to mitigate mental retardation |
| ZA200904826B (en) * | 2007-01-03 | 2010-09-29 | Cortex Pharma Inc | 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses |
| CA2674321A1 (en) | 2007-01-03 | 2008-07-17 | Cortex Pharmaceuticals, Inc. | 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses |
| NZ584098A (en) * | 2007-09-20 | 2012-05-25 | Cortex Pharma Inc | 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses |
-
2011
- 2011-04-12 US US13/085,241 patent/US20110257186A1/en not_active Abandoned
- 2011-04-13 AU AU2011239683A patent/AU2011239683A1/en not_active Abandoned
- 2011-04-13 KR KR1020127029867A patent/KR20130092976A/ko not_active Withdrawn
- 2011-04-13 JP JP2013505098A patent/JP2013523892A/ja active Pending
- 2011-04-13 CA CA2796345A patent/CA2796345A1/en not_active Abandoned
- 2011-04-13 EP EP11715842A patent/EP2558100A1/en not_active Withdrawn
- 2011-04-13 WO PCT/US2011/032325 patent/WO2011130411A1/en not_active Ceased
- 2011-04-13 RU RU2012148214/15A patent/RU2012148214A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013523892A (ja) | 2013-06-17 |
| RU2012148214A (ru) | 2014-05-20 |
| EP2558100A1 (en) | 2013-02-20 |
| WO2011130411A1 (en) | 2011-10-20 |
| KR20130092976A (ko) | 2013-08-21 |
| CA2796345A1 (en) | 2011-10-20 |
| US20110257186A1 (en) | 2011-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7519413B2 (ja) | 眼科用薬剤組成物、眼科用キット、及びその医学的応用 | |
| JP2010536797A5 (cg-RX-API-DMAC7.html) | ||
| JP2009511632A5 (cg-RX-API-DMAC7.html) | ||
| RS63136B9 (sr) | Lekoviti sastav koji sadrži tivozanib | |
| US20090118262A1 (en) | Non-Aqueous Water-Miscible Materials as Vehicles for Drug Delivery | |
| MXPA06000408A (es) | Suministro de un farmaco por medio de suministro periocular o subconjuntival de un profarmaco en una microparticula polimerica. | |
| JP2021518352A (ja) | チモロールを含む医薬組成物 | |
| JP2017503028A (ja) | 眼内血管新生及び/または漏出を治療するための組成物及び方法 | |
| US20170172959A1 (en) | D-serine for the treatment of visual system disorders | |
| US20110257186A1 (en) | Compositions and methods for treating visual disorders | |
| JP2019534269A5 (cg-RX-API-DMAC7.html) | ||
| AU2004296748B2 (en) | Prevention and/or reduction of photoreceptor degeneration with retinoids | |
| JP2013501794A (ja) | 目の疾患を治療するためのイソチオゾール | |
| CN117355292A (zh) | 用于预防或治疗眼病的抑制n-氧代吡啶化合物出现的眼科组合物 | |
| JP2002356431A (ja) | ステロイドを有効成分とする網脈絡膜疾患治療剤 | |
| CN111358751B (zh) | 眼用药物组合物、眼用药盒及其医药用途 | |
| US20130197002A1 (en) | Brimonidine for treating visual disorders mediated by central visual projections from the eye | |
| CA3036474C (en) | Therapeutic agent for an ophthalmic disease comprising a vegf receptor inhibitor | |
| US20130267488A1 (en) | Pharmaceutical formulation having neuroprotective activity | |
| HK40074896A (en) | Ophthalmic pharmaceutical composition, ophthalmic kit, and medical application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |